Protective effect of dienogest on chemotherapy-induced reduced fertility in female rats
Lab / animal
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
Dienogest administration protected female rats from chemotherapy-induced ovarian damage and subsequent reduced fertility by preserving ovarian follicle numbers and reducing apoptosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Reduced fertility is one of the main long-term consequences of chemotherapy given for lymphoma, leukemia, and other malignancies in young women. We examined with a female rat model whether and how dienogest, a fourth-generation progestin, modulates reduced fertility following exposure to gonadotoxic chemotherapy. Female rats were administered cyclophosphamide with or without GnRH agonist and different concentrations of dienogest for 20 days. Animals were sacrificed on Day 29, and the numbers of follicle at primordial, preantral and antral stage in the ovaries were counted histologically. Rats treated with sterile saline solution (as control), cyclophosphamide, cyclophosphamide plus GnRH agonist, and cyclophosphamide plus dienogest were also mated with male rats to evaluate their fertility and pregnancy outcomes. Cyclophosphamide significantly reduced the number of primordial follicles, whereas dienogest suppressed depletion of primordial follicle pool induced by chemotherapy. Although the rats exposed to cyclophosphamide alone failed to deliver live births, co-treatment with dienogest improved the pregnancy outcomes of treated rats. The protective effect of dienogest on chemotherapy-induced ovarian damage and reduced fertility was comparable to that of GnRH agonist. The present results suggest that the co-administration of dienogest and chemotherapy may be a useful strategy in preserving ovarian function and fertility in premenopausal women facing gonadotoxic chemotherapy.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (43)
- Comparative pharmacology of newer progestogens via openalex
- Dienogest in long-term treatment of endometriosis via openalex
- Effect of gonadotropin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat via openalex
- Efficacy of dienogest in thinning the endometrium before hysteroscopic surgery via openalex
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis via openalex
- Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women via openalex
- Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review) via openalex
- WITHDRAWN: Gonadotrophin-releasing hormone analogues for pain associated with endometriosis via openalex
- doi:10.1016/j.bpobgyn.2011.11.008 via openalex
- doi:10.1001/jama.1979.03300170023020 via openalex
- doi:10.1200/jco.2008.21.1839 via openalex
- doi:10.1016/j.fertnstert.2009.02.054 via openalex
- doi:10.1095/biolreprod57.2.420 via openalex
- doi:10.1007/bf03345616 via openalex
- doi:10.1093/humrep/dep469 via openalex
- doi:10.1093/humupd/dmh021 via openalex
- doi:10.1097/grf.0b013e3181f96b54 via openalex
- doi:10.1200/jco.2006.06.5888 via openalex
- doi:10.1055/s-0029-1210217 via openalex
- doi:10.1210/edrv.21.2.0394 via openalex
- doi:10.1093/humrep/14.7.1903 via openalex
- W2274370275 via openalex
- doi:10.1530/rep-06-0045 via openalex
- W6604571048 via openalex
- W6631968924 via openalex
- W6635969585 via openalex
- W6677071583 via openalex
- W6677128360 via openalex
- doi:10.1210/er.21.2.200 via openalex
- doi:10.3389/fnins.2013.00099 via openalex
- doi:10.1093/jncimonographs/lgi025 via openalex
- doi:10.1186/1477-7827-8-51 via openalex
- doi:10.1200/jco.2012.43.5511 via openalex
- doi:10.1002/1097-0142(19830801)52:3<435::aid-cncr2820520308>3.0.co;2-1 via openalex
- doi:10.1016/0890-6238(91)90097-y via openalex
- doi:10.1095/biolreprod24.4.913 via openalex
- W1531304895 via openalex
- W1603047561 via openalex
- doi:10.1016/s0890-6238(97)00034-8 via openalex
- doi:10.1016/j.fertnstert.2004.12.030 via openalex
- doi:10.1530/jrf.0.0170555 via openalex
- doi:10.1016/j.maturitas.2012.01.018 via openalex
- doi:10.1210/en.2002-0131 via openalex
Cited by (3)
- Hormonal Therapies before In-Vitro Fertilization in Women with Endometriosis 2024
- Hormonal Therapies before in vitro fertilization in women with endometriosis: The Minotaur's Labyrinth and the Ariadne's Thread 2024
- Dienogest suppresses the activation of primordial follicles and preserves the primordial follicle stockpile for fertility in mice 2018
Source provenance
- openalex
- last seen: 2026-05-11T06:17:40.080092+00:00
- pubmed
- last seen: 2026-10-08T21:14:41.184593+00:00
License: CC0
· commercial use OK